The DOI matches its Crossref record; 658 of the 659 references it cites were found in a registry or an index.
Designer drugs: mechanism of action and adverse effects
Open accessAbstract
Psychoactive substances with chemical structures or pharmacological profiles that are similar to traditional drugs of abuse continue to emerge on the recreational drug market. Internet vendors may at least temporarily sell these so-called designer drugs without adhering to legal statutes or facing legal consequences. Overall, the mechanism of action and adverse effects of designer drugs are similar to traditional drugs of abuse. Stimulants, such as amphetamines and cathinones, primarily interact with monoamine transporters and mostly induce sympathomimetic adverse effects. Agonism at μ-opioid receptors and γ-aminobutyric acid-A (GABA A ) or GABA B receptors mediates the pharmacological effects of sedatives, which may induce cardiorespiratory depression. Dissociative designer drugs primarily act as N -methyl- d -aspartate receptor antagonists and pose similar health risks as the medically approved dissociative anesthetic ketamine. The cannabinoid type 1 (CB 1 ) receptor is thought to drive the psychoactive effects of synthetic cannabinoids, which are associated with a less desirable effect profile and more severe adverse effects compared with cannabis. Serotonergic 5-hydroxytryptamine-2A (5-HT 2A ) receptors mediate alterations of perception and cognition that are induced by serotonergic psychedelics. Because of their novelty, designer drugs may remain undetected by routine drug screening, thus hampering evaluations of adverse effects. Intoxication reports suggest that several designer drugs are used concurrently, posing a high risk for severe adverse effects and even death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The precipitous increase in novel and designer drugs (eg, cathinones, amphetamines) in the market complicates the clinical picture.3”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increases in drug and opioid-involved overdose deaths – United States, 2010-2015
Rudd, R. A., Seth, P., David, F., & Scholl, L. (2016) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm655051e1 · Cited by 2,194
Cocaine Receptors on Dopamine Transporters Are Related to Self-Administration of Cocaine
Ritz, M. C., Lamb, R. J., Goldberg, S. R., & Kuhar, M. J. (1987) · Science · doi:10.1126/science.2820058 · Cited by 2,180
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017
Scholl, L., Seth, P., Kariisa, M., Wilson, N., & Baldwin, G. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm675152e1 · Cited by 1,731
Endocannabinoid-Mediated Control of Synaptic Transmission
Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009) · Physiological Reviews · doi:10.1152/physrev.00019.2008 · Cited by 1,529
Anis, N. A., Berry, S. C., Burton, N. R., & Lodge, D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb11031.x · Cited by 1,399
The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)
Green, A. R., Mechan, A. O., Elliott, J. M., O’Shea, E., & Colado, M. I. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.3 · Cited by 1,272
European Monitoring Centre for Drugs and Drug Addiction
Anderson, M. (2014) · European Union regulations | European Encyclopedia of law · Cited by 1,213
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211 · cited 5×
“Similar to other psychedelics, tryptamine psychedelics alter perception and can induce psychological disturbances in users, including acute psychosis (Meatherall and Sharma 2003; Nichols 2004, 2016; Shulgin and Shulgin 1997; Taljemark and Johansson 2012).”
InfluentialMechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
Research works printed but not linked: 5
- Heim R (2004) Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur: Entwicklung eines neuen Struktur-Wirkungskonzepts. Dissertation, Freie Universität Berlin. https://refubium.fu-berlin.de/bitstream/handle/fub188/11995/0_RalfHeimTitelblatt.pdf?sequence=1&isAllowed=y. Accessed 7 Jan 2020
- Sanchez S (1929) Sur un homologue de l’éphédrine. Bull Soc Chim Fr 45:284–286
- Thorlacius K, Borna C, Personne M (2008) Bromo-dragonfly–livsfarlig missbruksdrog. Kan ge vävnadsnekros, visar det första beskrivna fallet. Lakartidningen 105(16):1199–200
- Topeff J, Ellsworth H, Willhite L, Bangh S, Edwards E, Cole J (2011) A case series of symptomatic patients, including one fatality, following 2C-E exposure. Clin Toxicol (Phila) 49:526
- Trachsel D, Lehmann D, Enzensperger C (2013) Phenethylamine: von der Struktur zur Funktion. Nachtschatten Verlag, Solothurn
Cited by
New psychoactive substances: a review and updates
Shafi, A., Berry, A. J., Sumnall, H., Wood, D. M., & Tracy, D. K. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320967197 · Cited by 347
The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
(2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001299 · Cited by 78
Understanding the Mechanisms of Action and Effects of Drugs of Abuse
Anghel, D.-M. C., Nițescu, G. V., Tiron, A. T., Guțu, C. M., & Baconi, D. L. (2023) · Molecules · doi:10.3390/molecules28134969 · Cited by 124
A review of synthetic cathinones emerging in recent years (2019–2022)
Kuropka, P., Zawadzki, M., & Szpot, P. (2022) · Forensic Toxicology · doi:10.1007/s11419-022-00639-5 · Cited by 79
Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017–2020: A Review
Mohr, A. L. A., Logan, B. K., Fogarty, M. F., Krotulski, A. J., Papsun, D. M., Kacinko, S. L., Huestis, M. A., & Ropero‐Miller, J. D. (2022) · Journal of Analytical Toxicology · doi:10.1093/jat/bkac023 · Cited by 87
Metadata
- Authors
- Luethi, D., & Liechti, M. E.
- Affiliations
- TU Wien (AT)
- University of Basel (CH)
- Corresponding author
- Luethi, Dino
- Venue
- Archives of Toxicology
- Published
- 2020-04
- Volume
- 94
- Issue
- 4
- Pages
- 1085-1133
- ISSN
- 0340-5761 (ISSN-L)
- 1432-0738
- PMC
- PMC7225206
- OpenAlex
- W3014121938
- Cited by
- 262
- References
- 659
- Citations by year
- 2026: 29 · 2025: 43 · 2024: 43 · 2023: 42 · 2022: 55 · 2021: 35 · 2020: 13
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-03-03)
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 5 d)
- Locations
- Archives of Toxicology (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- edoc (University of Basel) (submittedVersion)
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P2BSP3_181809)
- Bundesamt für Gesundheit (16.921318)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- new psychoactive substances, mechanism of action, adverse drug reactions, stimulants, cathinone, monoamine transporters, sympathomimetic effects, sedatives, mu-opioid receptor agonism, GABA receptors, cardiorespiratory depression, dissociative drugs, NMDA receptor antagonists, ketamine, synthetic cannabinoids, CB1 receptor, serotonergic psychedelics, 5-HT2A receptor, drug screening, polydrug use
- MeSH terms
- Central Nervous System Stimulants, Cannabinoids, Hallucinogens, Humans, Psychotropic Drugs, Serotonin, Illicit Drugs, Designer Drugs, Molecular Structure, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Designer drugs: mechanism of action and adverse effects. https://app.cochat.ai/papers/10.1007/s00204-020-02693-7
- The paper
- Luethi, D., & Liechti, M. E. (2020). Designer drugs: mechanism of action and adverse effects. Archives of Toxicology. https://doi.org/10.1007/s00204-020-02693-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.